3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Phase 2
1
Status
Recruiting
1
Completed
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
2
Gastrointestinal
1
Conditions
Prostatic Neoplasms
1
Primary Dysautonomias
1
Kidney Diseases
1
Hypertension
1
High Risk Prostate Cancer
1
Interventions
Docetaxel
229
Radiotherapy
206
Magnetic Resonance Spectroscopy
204
Radiosurgery
176
Gemcitabine
155
pembrolizumab
152
Nivolumab
147
enzalutamide
140
Prednisone
129
Cisplatin
123
Leuprolide
119
Androgen Antagonists
117
Abiraterone Acetate
114
Sunitinib
106
Specimen Handling
94
Surveys and Questionnaires
91
Goserelin
91
bicalutamide
90
Carboplatin
88
Ipilimumab
82
gallium 68 PSMA-11
80
Blood Specimen Collection
78
Everolimus
73
apalutamide
72
Radiation
71
Standard of Care
68
Biopsy
68
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
66
Paclitaxel
64
Cyclophosphamide
62
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
OTHER
×
Receptors, Androgen
×
Genitourinary
×
Clear all
NCT05700903
2026-03-02
ARCH
University of Colorado, Denver
Phase 4
Completed
10 enrolled
NCT06758882
2025-01-06
STAPLE
A.O.U. Città della Salute e della Scienza
Phase 2
Recruiting
94 enrolled